Vitamin A deficiency has been known for a long time to be accompanied with immune deficiency and susceptibility to a wide range of infectious diseases. Increasing evidence suggests that retinoic acids derived from vitamin A are involved in the functional regulation of the immune system. Of the two groups of retinoid receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs) all-trans and 9-cis retinoic acids are high affinity ligands for RARs and 9-cis retinoic acid additionally binds to RXRs. In cells, at high concentrations, all-trans retinoic acid can be converted to 9-cis retinoic acid by unknown mechanisms. Apoptosis plays a major role in shaping the T cell repertoire and one way in which retinoids may affect immune functions is to influence the various apoptosis pathways. Indeed, it has been shown that retinoic acids can induce apoptosis, increase the rate of dexamethasone-induced death and inhibit activation-induced death of thymocytes and T lymphocytes. Therefore, retinoids together with glucocorticoids may be involved in regulating positive and negative selection of T lymphocytes. Here we demonstrate that retinoids can induce apoptosis of T cells through the stimulation of RARg. Specific stimulation of RARa, on the other hand, prevents both RARg-dependent and TCR-mediated cell death. In all these functions 9-cis retinoic acid proved to be more effective than all-trans retinoic acid suggesting the involvement of RXRs. Based on these results a possible mechanism through which costimulation of RARs and RXRs might affect spontaneous and activation-induced death of T lymphocytes is proposed.
Apoptosis induction via distinct signalling pathways shapes the T cell repertoire
Apoptosis or active cell death, plays an essential role in shaping the T lymphocyte repertoire which may influence the control of the body's immune responses. Lymphocytes differentiating in the thymus randomly generate their TCRs and become selected in the CD4 + CD8 + stage. Those cells which express potentially autoreactive TCR undergo apoptosis after interacting with the antigen presenting cells (APC) . This selection process can be studied using T cell hybridomas (Ucker et al, 1989) and can be mimicked by stimulating the TCR-associated CD3 molecule with a specific antibody or by simultaneous addition of phorbol-dibutyrate and Ca 2+ -ionophore in vitro which mimicks the TCR-induced signal transduction pathway (Iseki et al, 1991) . Those cells which express functionally acceptable TCR become positively selected and differentiate into mature CD4 + or CD8 + single positive thymocytes (Groettrup and von Boehmer, 1993) . In these cells bcl-2, an apoptosis inhibitory protein becomes upregulated and protects cells against death (Sentman et al, 1991; Szondy, 1997) . However, the majority of T cells express functionally unacceptable TCRs and enter the apoptotic programme through a`default pathway' which is accelerated when cells are exposed to high levels of glucocorticoids (Cohen, 1993) , or by treatments leading to DNA breaks ± ionizing radiation, 2-chlorodeoxyadenosine addition or inhibition of topoisomerase II by etoposide Ming-Sun et al, 1994; Szondy, 1995) . The apoptotic programme induced in each of these cases works via different signal transduction pathways . Stimulation of TCR and CD3 induces changes in second messenger systems (McConkey et al, 1992) , glucocorticoids bind to steroid receptors, while inhibition of topoisomerase II or irradiation causes direct DNA damage. Each of these pathways appear to induce distinct sets of genes. The transcripts RP-2 and RP-8 are expressed in thymocytes following treatment with glucocorticoids (Owens et al, 1991) . DNA damage leads to p53 induction (Lowe et al, 1993; Szondy, 1995) ; thymocytes lacking p53 are resistant to the lethal effects of ionizing radiation or etoposide, but not to other treatments (Lowe et al, 1993; Clarke et al, 1993) . The immediate-early gene, nur 77, on the other hand, is induced in response to TCR signals but not by glucocorticoids or ionizing radiation . Antisense inhibition of the expression of nur 77 prevents apoptosis in TCR stimulated cells but not if death was induced by other stimuli .
Mature T lymphocytes entering the periphery are relatively resistant to various apoptosis inducing signals due to the constant expression of bcl-2 (Yang and Korsmeyer, 1996; Szondy, 1997) . After mitogenic stimulation, however, their proliferation and survival depends on IL-2 production (Duke and Cohen, 1986) which upregulates bcl-X L , another apoptosis inhibitory protein (Yang and Korsmeyer, 1996) . After clearance of antigen, in the absence of further antigenic stimulation IL-2 production is declined and many of the lymphocyte clones die due to the lack of survival signal (mechanism of immune down-regulation). In the case of chronic activation, on the other hand, the limitation of the immune response occurs by a different mechanism. TCR stimulation leads to fasL and TNF production, and these cytokines initiate the apoptotic programme in the fas or TNF receptor bearing, apoptosis sensitive chronically activated peripheral CD4+ T cells (Dhein et al, 1995) and CD8+ T cells (Zheng et al, 1995) (mechanism of feed back control of the T cell proliferation). This feed back control mechanism may lead to a pathologically high rate of lymphocyte apoptosis under certain pathological conditions such as HIV infection (Gougeon, 1995) , where an enormous rate of fas ligand production due to the viral proteins gp120 and tat can be detected (Baumler et al, 1996) .
In¯uence of retinoids on various forms of T cell death
Vitamin A deficiency has been known for a long time to be accompanied with immune deficiency and susceptibility to a wide range of infectious diseases (Goodman, 1994) . In vitamin A deficient animals a marked atrophy of the thymus and the spleen has been observed (West et al, 1989) . On the other hand, retinoids at high doses are toxic and cause involution of lymphoid organs, in particular of the thymus (Dennert and Lotan, 1978) , whereas moderate, subtoxic doses of retinoids have been reported to result in a significant increase in thymus weight, numbers of thymic small lymphocytes (Seifert et al, 1981) , and in cellularity of lymph nodes (Taub et al, 1970) . Suggestions have been made that the active metabolites of vitamin A, that mediate its effects on the immune system, are the retinoic acids (Mendelsohn et al, 1994; Zhao and Ros, 1995) ± all-trans RA and 9-cis RA ± which are ligands for the nuclear retinoic acid receptor family (Mangelsdorf, 1994) .
Since apoptosis plays a major role in shaping the T cell repertoire, one way in which retinoids can affect the immune system is to influence various forms of T cell death. Indeed it has been demonstrated that retinoids can enhance the rate of glucorticoid-induced death (Iwata et al, 1992; Fe Â su È s et al, 1995) , and can inhibit the TCR-mediated death of thymocytes and T cell hybridomas (Iwata et al, 1992; Yang et al, 1993; Fe Â su È s et al, 1995) but have no effect on the p53-induced death (Fe Â su È s et al, 1995) . While the exact mechanism of activation-induced death of thymocytes is not known, it has been demonstrated in the case of T cell hybridomas that the mechanism by which retinoids inhibit activation-induced death is inhibition of fasL production (Yang et al, 1995a) . Based on these observations all-trans RA was successfully used in in vitro and in vivo to inhibit activation-induced T cell death of HIV+ individuals (Yang et al, 1995b) . It was also shown that this protection concerns mainly the CD4+ T lymphocytes and based on the down regulation of fasL production (Szondy et al, unpublished observation) . Additionally, retinoids were found to be inducers of apoptosis by themselves (Fe Â su È s et al, 1995; Szondy et al, 1997) . In each of these phenomena 9-cis RA has proved to be 10 ± 50 times more effective than all-trans RA.
Interestingly most of the previously observed biological effects of retinoids on T cell death can be mimicked by glucocorticoids as well. Glucocorticoids are ligands for the glucocorticoid receptor family, which together with the retinoid receptors, belong to (though different subclasses of) the same nuclear receptor superfamily (Mangelsdorf et al, 1995) . Glucocorticoids themselves are potent inducers of T cell death (Cohen, 1993; Szondy, 1997) , enhance the effect of retinoids (Iwata et al, 1992) , inhibit activationinduced death of thymocytes (Iseki et al, 1991) and prevent apoptosis of T lymphocytes by down regulation of fasL production (Yang et al, 1995a) . Other members of this receptor superfamily (thyroid hormones or vitamin D) have no effect on apoptosis of T lymphocytes (Iwata et al, 1992) .
What may be the biological significance of these findings? The concentration of all-trans retinoic acid needed to initiate or inhibit certain forms of apoptosis in thymocytes is much higher than its physiological plasma level in vivo estimated to be 12 nM (De Leenheer et al, 1982; Reichert and Fe Â su È s, 1991; Lehman and Franz, 1996) . However, the concentration of it may vary around the cells due to a local retinoid production (Wagner et al, 1992) . 9-cis RA was shown to be generated by isomerisation of all-trans RA being in equilibrium with and depending on the concentration of all-trans RA (Urbach and Rando, 1994) . Since the apoptosis-regulating effect of 9-cis retinoic acid occurs at a much lower concentration, in case the circulating all-trans retinoic acid is converted to the 9-cis ligand in sufficient amount in thymocytes, the RAmediated cell death is initiated. This may be one of the critical events in the initiation of apoptosis of those CD4 + CD8 + double positive thymocytes which have lowaffinity TCR and have not been positively selected or eliminated by the negative selection pathway mediated by high-affinity TCR-self antigen interaction. The large majority of thymocytes die through this so called`default death pathway' (Fe Â su È s, 1991), but the initiator of apoptosis in these cells has not been clarified yet. Though glucocorticoids certainly accelerate the default pathway of apoptosis both in vivo and in vitro, this does not necessarily mean that the steroids are the only physiological initiators of the death pathway in these cells. One may speculate that the simultaneous enhancing effect of these two ligands may lower the effective concentration for both ligands to induce apoptosis in a large population of thymocytes.
Glucocorticoids, retinoids and the TCR seem to regulate positive and negative selection of thymocytes in a coordinated manner. Glucocorticoids, which also inhibit TCR-induced cell death, were suggested to be required for the transition from CD4 7 CD8 7 to CD4 + CD8 + cells and additionally to increase the threshold at which an antigen is recognised as high affinity ligand and initiates negative selection (King et al, 1995) . At low concentrations of glucocorticoids retinoids proved to be additive in inhibiting TCR-mediated cell death (Iwata et al, 1992) suggesting that retinoids and glucocorticoids may simultaneously affect the number of positively selected thymocytes. Additionally retinoids may also affect the differentiation process since selective overexpression of the RARg receptor in the T cell compartment can affect the ratio of CD8+ and CD4+ T cells (Pohl et al, 1993) .
Molecular mechanism of action of retinoic acids
All-trans and 9-cis RA are formed within most cells and are physiological ligands for the retinoid receptors (RARs, RXRs) (Chambon, 1994) . These receptors are ligand dependent transcription factors which bind to specific hormone response element (RARE, RXRE) and transactivate specific target genes (Rastinejad et al, 1995) . All-trans RA and 9-cis RA are equipotent in activating RAR, while activation of RXR by alltrans RA is 50-fold less than by 9-cis retinoic acid (Heyman et al, 1992) . Though all-trans RA does not bind to RXR receptors, the latest observation is explained by conversion of the all-trans RA to 9-cis RA within the cells (Urbach and Rando, 1994) reaching an intracellular concentration sufficient to activate RXR receptors at high extracellular concentrations of all-trans RA. Under experimental conditions retinoic acid receptors function in the form of either RAR/ RXR heterodimers or RXR/RXR homodimers in the presence of RAs (Zhang et al, 1992) . It is, however, still an open question whether RXR/RXR homodimer formation can occur under conditions when RXR is expressed at physiological concentrations in cells, though some experiments suggest that it may be so (McCaffery et al, 1993) . Additionally, RXR can form heterodimers with various other members of the steroid/thyroid/retinoid receptor family such as thyroid receptor, vitamin D 3 receptor, COUP-TF (Kliewer et al, 1992a,b; Yu et al, 1991) . The presence of RXR in these heterodimers is needed to enhance the cooperative binding of these receptors to the DNA, and the transcriptional activation requires only the presence of the cognate vitamin D 3 receptor, thyroid receptor or RAR ligands, but can be modulated by the simultaneous binding of the RXR ligand (Yu et al, 1991) . These complex interactions and the existence of multiple retinoic acid nuclear receptors (RARa, b and g) as well as retinoid X receptors (RXRa, b and g), differentially expressed in various tissues and cell types, explain the pleiotropic effects of retinoids in practically all types of cells in the mammalian organism.
Though a partial functional redundancy exists between the three types of RAR (Mendelsohn et al, 1994; Taneja et al, 1995) the time and tissue specific expression of the various RARs during development and the observed malformations in RAR null mice (Lufkin et al, 1993; Lohnes et al, 1993) suggest that at wild-type expression levels various RAR types exert different regulatory roles. RXRa knock out mice also show various malformations suggesting that RXRa has an important role in the transduction of a retinoid signal during development (Kastner et al, 1994) . The RXRa and b receptors, however, have a widespread (possibly ubiquitous) expression pattern during mouse development and though RXRg transcripts appear to have a more restricted distribution, RXRg null mice are apparently normal (Krezel et al, 1996) . Additionally, RXRa +/7 /RXRb 7/7 /RXRg 7/7 mutant mice are viable demonstrating that one copy of RARa is sufficient to perform most of the functions of the RXRs. These data suggest that the specificity of the retinoid signalling pathway is determined by the three types of RARs within the RAR/RXR heterodimers and the presence or costimulation of RXRs may affect these signalling pathways independently of their family types.
Involvement of RAR and RXR receptors in regulating spontaneous death of thymocytes
Thymocytes and T cell hybridoma cells express RARa and RARg but not RARb (Meco et al, 1994; Szondy et al, 1997a) . This means that in these cells both RARa/RXR and RARg/ RXR heterodimers may function in the retinoid signal transduction pathway involved in regulation of T cell death.
In experiments carried out in our laboratories selective RAR subtype agonists, antagonists and RXR agonists (Table 1) were used to investigate which retinoid receptors mediate retinoid actions (Szondy et al, 1997a) . We have previously shown that retinoic acids can induce death in mouse thymocytes (Fe Â su È s et al, 1995). 9-cis RA was found to be more effective than all-trans RA suggesting that RXRs might be involved. Indeed, addition of an RXR selective compound (CD2425) at 0.1 mM concentration shifted the dose curve of the all-trans RA to that of the 9-cis RA. However, neither physiological concentrations of all-trans RA nor the RXR agonist alone were able to induce cell death suggesting that both RARs and RXRs participate in the phenomenon.
Using various RAR subtype selective agonists it was found that neither RARa nor RARb agonists can induce H]-CD367 as radiolabelled reference retinoid, that binds with high af®nity to RARa, RARb, and RARg (K d =3.7, 4.1 and 1.5 nM, respectively) but does not transactivate RXR. The assays were performed as previously described (Szondy et al, 1997a) using nuclear extracts of COS-7 cells transfected with pSG-5-derived expression vectors for RARa, RARb or RARg (provided by Dr. M. Pfahl, La Jolla Cancer Research Foundation, La Jolla, CA). Because no radiolabelled RXR speci®c ligand for binding studies was available, interaction of the retinoids with this receptor type was assessed by a functional transactivation assay as previously described (Szondy et al, 1997a) cell death. Four types of RARg agonists tested (Table 1) , however, proved to be effective inducers of apoptosis. Additionally, an RARg antagonist (CD2665) at 3 mM concentration prevented cell death induced by either 9-cis RA (1 mM) or by combination of all-trans RA (0.1 mM) and an RXR analogue (0.1 mM) proving that the induction of cell death by retinoids is mediated via the RARg receptor. With nearly equal K d for RARg the ability of the RARg agonists to induce apoptosis was found to be strongly dependent on their specificity to RARg versus RARa (Table 2 ). This observation suggests that costimulation of RARa may suppress the RARg-mediated cell death pathway. Indeed, addition of increasing concentrations of an RARa analogue (CD336) inhibited the RARg-mediated cell death, while combination of an RARa antagonist (CD2503 0.1 mM) with all-trans RA at concentrations where all-trans RA alone was not sufficient to initiate apoptosis resulted in cell death induction. These data demonstrate that the action of RARa and RARg are balanced and no cell death can be observed when they are costimulated by physiological concentrations of alltrans RA. If however, RXR is also stimulated by addition of an RXR analogue or in case of 9-cis RA the RARg pathway of cell death is initiated. According to these data the role of the stimulation of the RXR is to facilitate the RARg-mediated cell death pathway (Figure 1 ).
Involvement of various RAR and RXR receptors in regulating TCR-mediated death of T lymphocytes
TCR-mediated death of both thymocytes and T cell hybridomas were shown to be inhibited by increasing concentrations of all-trans and 9-cis RA (Iwata et al, 1992; Yang et al, 1993; Fe Â su È s et al, 1995) . 9-cis RA was found to be 10 times more potent suggesting again that RXR receptors are involved in the process. Indeed, studies, carried out on T cell hybridomas transfected with cDNA encoding RXRb, have shown that cells that overexpressed RXRb were more sensitive to 9-cis RA rescue from TCR-mediated death. In contrast, cells expressing the dominant-negative RXRb could not be rescued from death with 9-cis RA (Yang et al, 1995c) . Addtionally in wild-type cells, an RAR-selective synthetic ligand had little effect, while simultaneous addition of an RXR selective agonist prevented TCR-mediated apoptosis (Bissonette et al, 1995; Yang et al, 1995c) . Since nur77 which is also a member of the steroid/ thyroid/retinoid nuclear receptor superfamily (Mangelsdorf et al, 1995) was shown to be involved in the signal transduction of TCR-mediated death , suggestions were made that nur77 functions in the monomer form to upregulate fasL production, while RXR upon ligand binding forms a heterodimer with it and inhibits its action (Okabe and Nawata, 1996) . However, selective RXR analogues alone inhibit TCRmediated death only at concentrations much higher than that required for 9-cis RA. Simultaneous addition of the RAR-and RXR-selective retinoids, on the other hand, completely prevent activation-induced apoptosis at concentrations where either alone had relatively little protective effect (Bissonette et al, 1995; Yang et al, 1995c) . These data suggest that binding of not only RXRs but also RARs are required for efficient inhibition of TCR-mediated death.
In similar experiments described previously (Szondy et al, 1997a) we have found that, in agreement with the expression pattern, an RARb-selective compound cannot Figure 1 Possible model for the action of RARs and RXRs in regulating various apoptosis pathways of thymocytes. Circles represent binding of agonists while squares binding of antagonists. All-trans retinoic acid is at physiological concentrations. Please, note that RXR costimulation by 9-cis RA results in different outcome in the two cell death pathways: 1, induction of apoptosis by suspending the balance between the stimulation of the two RARs via facilitating the RARg pathway; 2, prevention of activation-induced death by suspending the balance between the stimulation of the two RARs via facilitating the RARa pathway inhibit activation-induced apoptosis in thymocytes and T cell hybridomas. RARg-selective compounds (CD437, CD2325 and CD2019 with an EC 10 value of 6.3 nM, 1.3 mM and 4.5 mM, respectively), on the other hand, stimulated and did not inhibit TCR-mediated death. Two RARa-selective compounds (CD336 and CD2081) at a concentration of 0.1 mM, however, efficiently inhibited TCR-mediated death (unpublished observations). Their inhibitory effect corresponded well to their specificity for the RARa receptor and to the downregulation of fasL production in a T cell hybridoma cell line (unpublished observations), suggesting that RARa alone might be involved in blocking death. Indeed, an RARa antagonist (CD2503) at 1 mM concentration prevented inhibition of TCR-mediated death achieved by addition of either 9-cis RA (1 mM) alone or a combination of all-trans RA (0.1 mM) and an RXR analogue (CD2425 0.1 mM). Why do RAR panagonists (Yang et al, 1995c) or low (physiological) concentrations of all-trans RA not prevent the TCR-mediated death when they are also potent RARa activators? Since the RARa specific compounds used in our study and all-trans RA have similar K d for the RARa, the only explanation for the lack of the inhibitory effect is that the panagonist all-trans RA costimulates RARg as well. Indeed, addition of an RARg antagonist (CD2665) in 0.1 mM concentration shifted the inhibitory dose curve of all-trans RA to that of the 9-cis RA (unpublished observation). Furthermore, increasing concentrations of the RARg analogue (CD437) prevented inhibition of activationinduced death by the RARa analogue (unpublished observation). These data suggest that when costimulated (in case of physiological concentration of all-trans RA) the apoptosis stimulatory action of RARg and the apoptosis inhibitory action of RARa are balanced and no change in the cell death rate can be observed. Since costimulation of RXR receptors makes both all-trans RA and a panangonist RAR analogue (Bissonette et al, 1995; Yang et al, 1995c) effective apoptosis inhibitors, we suggest that the role of RXR costimulation in the inhibition of TCR-mediated death is to facilitate the RARa-mediated inhibitory pathway (Figure 1 ).
Possible molecular explanation of the effects of RARa or RXR costimulation on the apoptosis machinery
It has already been demonstrated that RXRs are not always passive participants within the various transcription factor heterodimers in regulation of transciption. In some cases both the specific ligand and 9-cis RA can turn on transcription if, however, both ligands are present the transcription rate is enhanced (Mekherjee et al, 1997) . In some other cases additional binding of 9-cis RA inhibits transcription (Haussler et al, 1995) . In the case of inhibitory thyroid hormone response elements, binding of 9-cis RA releases RXR from the thyroid receptor/RXR heterodimers and suspends thyroid mediated inhibition of transcription (Cohen et al, 1995) . Our data are the first to show that activation of RXRs by 9-cis RA or other ligands can regulate antagonistic RARa and RARgmediated processes.
Our studies are not sufficiently detailed to decide the precise mechanism by which stimulation of RARa leads to the observed inhibition of RARg-mediated effects. One possibility is that RARa acts downstream of RA-RARg binding initiating various anti-apoptotic processes. Alternatively both RARa and RARg may regulate the transcription of specific proteins responsible for initiation of apoptosis. The specific proteins responsible for initiation of the RARgmediated or TCR-induced death of thymocytes have not been determined yet. Since, however, those RARg analogues which have higher affinity for RARa require higher concentrations to induce the same rate of apoptosis or to stimulate the TCR-mediated apoptosis, one possibility is that the co-stimulated RARa may compete with RARg for RXR binding or costimulated RARa/RXR heterodimers may compete with RARg/RXR heterodimers for DNA binding or transactivation sites. Stimulation of RXR in the same setting might facilitate binding of one or the other RAR receptor to the RXR receptor or binding of the RAR/RXR heterodimer to the DNA. Interestingly, RXR costimulation results in a different outcome in the two cell death pathways: in apoptosis induction the RARg occurs while in inhibition of TCR-mediated death the RARa pathway is activated. This may suggest that other transcription factors or retinoid receptor phosphorylation induced by the TCR signalling pathway are also involved in the retinoid receptor interplay.
From this point of view it is worth noting that the expression of tissue transglutaminase, an effector element of apoptosis (Fe Â su È s et al, 1987; Piacentini et al, 1994) was increased in thymocytes if apoptosis was induced via either the RARg (Szondy et al, 1997a) or the TCR-mediated pathway (Szondy et al, 1997b) in vivo and was not if RARa was costimulated. The promoter of this protein contains a 30-base pair retinoid response element (mTGRARE1) which consists of three hexanucleotide halfsites in DR7/DR5 motif. This response element binds both RAR/RXR heterodimers and RXR homodimers, can be partially activated by RAR or RXR agonists, but for the full activation the panagonist 9-cis RA is required (Nagy et al, 1996) . It is conceivable to believe that genes with such regulatory elements may be targets of the complex effects of retinoids described above.
Perspectives
Our findings suggest that both the type of retinoids available and fine tuning of RAR expression leading to various RARa/ RARg activation ratios in a thymocyte cell population may be determining factors for a cell to stay alive or to die.
The tissue distribution of the RARg transcript suggests a role for this receptor in morphogenesis, chondrogenesis, and differentiation of squamous epithelia . Null mutant mice of all RARg isoforms exhibit growth deficiency, early lethality, various forms of embryonic malformation and squamous metaplasia at ectopic locations ; several of the observed phenotypic changes may be explained by the perturbation of programmed cell death during development. RARg together with RARa plays a critical role in maintaining keratinocyte differentiation and cornification (Saitou et al, 1995) ; cornification and apoptosis are closely linked phenomena and both may occur and be regulated by retinoids, perhaps through RARg, in the skin (Polakowsaka, 1994) . These data suggest that the physiological importance of retinoid-induced apoptosis through RARg may not be restricted to the thymus and the immune system. Furthermore, there are significant therapeutic implications of the existence of a well-characterised, retinoid-initiated apoptosis pathway. If the presence of RARg in a cell type renders it susceptible to apoptosis (Marshall et al, 1995; Fanjul et al, 1996; Melino et al, 1997a,b) cell death will be initiated by addition of RARg-selective compounds. If the g receptor is expressed in malignant or autoreactive cell populations (or introduced into such population by gene transfer) these cells might be eliminated by apoptosis as a part of a new therapeutic strategy against cancer or autoimmune diseases. In this context it is worth noting that recently new retinoid structures were identified which were highly effective against lung cancer cells and various other tumours via inducing apoptosis (Lu et al, 1997) . Interestingly, all the effective compounds bound preferentially to RARg, providing additional evidence for a more general importance of the RARg mediated cell death pathway. Furthermore, our data also suggest the RARg apoptosis pathway can be potentiated by the administration of either RARa-antagonists or RXR agonists thus providing the basis of appropriately balanced and perhaps cell type specific therapeutic protocols for retinoids.
Pathologically high level of fasL production has been suggested to mediate apoptosis of lymphocytes in HIV+ individuals (Gougeon, 1995) , cell death of hepatocytes in acute viral hepatitis or to provide protection against cytotoxic T lymphocytes by some tumours. In these cases a possible down regulation of fasL production by RARa selective compounds could prevent pathological rate of apoptosis and elimination of tumour killing lymphocytes. These data suggest that selective retinoid compounds may be a powerful therapeutics in the near future via regulating various cell death pathways.
